Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
16 studies found for:    weill | Open Studies | "Liver Diseases"
Show Display Options
Rank Status Study
1 Unknown  The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
Conditions: Hepatic Encephalopathy;   Hepatitis C;   Liver Cirrhosis
Intervention: Drug: Rifaximin (drug)
2 Recruiting Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Condition: Liver Disease
Interventions: Drug: sofosbuvir/ledipasvir;   Drug: sofosbuvir;   Drug: Ribavirin
3 Recruiting Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
Condition: Non Alcoholic Steatohepatitis (NASH)
Interventions: Drug: Obeticholic Acid;   Drug: Placebo
4 Unknown  Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium
Condition: Hepatic Fibrosis
Intervention: Procedure: MRI of liver
5 Unknown  Effect of Large Volume Paracentesis on Fatigue in Cirrhosis
Conditions: Ascites;   Fatigue;   Cirrhosis
6 Not yet recruiting Safety Study of Gene Transfer Vector to Treat alpha1-antitrypsin Deficiency
Condition: alpha1-antitrypsin Deficiency
Intervention: Genetic: AAVrh.10halpha1AT
7 Unknown  Rifaximin Versus Lactulose in Renal Failure
Conditions: Liver Cirrhosis;   Renal Failure
Interventions: Drug: Rifaximin;   Drug: Lactulose
8 Unknown  Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Conditions: Thrombocytopenia;   Hepatitis C;   HIV Infections
Intervention: Drug: Anti-D
9 Recruiting Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT);   Drug: Dasabuvir (DSV);   Drug: Ribavirin (RBV)
10 Recruiting Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
Conditions: HIV-1 Infection;   Hepatitis
Interventions: Drug: Ribavirin;   Drug: Sofosbuvir;   Drug: Ledipasvir/Sofosbuvir
11 Recruiting Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Condition: Unresectable Hepatocellular Carcinoma
Intervention: Device: TheraSphere
12 Recruiting Study of Oral Treatments for Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: sofosbuvir/ledipasvir;   Drug: ombitasvir/paritaprevir/ritonavir;   Drug: elbasvir/grazoprevir;   Drug: Dasabuvir
13 Recruiting Phase 3 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cirrhosis
Condition: Liver Cirrhosis, Biliary
Interventions: Drug: Obeticholic Acid (OCA);   Drug: Placebo
14 Recruiting HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network
Condition: Hepatitis C
15 Recruiting A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: LY2157299;   Drug: Sorafenib
16 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Carcinoma Breast Stage IV;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Urinary Bladder Neoplasms;   Cervical Cancer;   Endometrial Cancer;   Follicular Thyroid Cancer;   Glioblastoma Multiforme
Intervention: Drug: IMMU-132

Indicates status has not been verified in more than two years